Trial Profile

A phase I, open-label, single-dose study to evaluate the effect of severe renal impairment on the pharmacokinetics of fenebrutinib

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fenebrutinib (Primary)
Indications Multiple sclerosis
Focus Pharmacokinetics
Sponsors Genentech

Most Recent Events

13 May 2024 Status changed from not yet recruiting to recruiting.
07 May 2024 Planned initiation date changed from 20 Oct 2023 to 6 Jun 2024.
07 May 2024 Planned End Date changed from 11 May 2024 to 25 Dec 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com